Our latest

News

Raising Pancreatic Cancer Awareness Through Patient Voices 

Raising Pancreatic Cancer Awareness Through Patient Voices 

Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador

Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador

Mauna Kea Technologies Announces Review of Strategic Alternatives

Mauna Kea Technologies Announces Review of Strategic Alternatives

Mauna Kea Technologies Provides an Update on Its Recent Developments

Mauna Kea Technologies Provides an Update on Its Recent Developments

Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance

Mauna Kea Technologies Announces New Positive Clinical Results for Cellvizio in Food Intolerance

Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales

Mauna Kea Technologies Reports H1 2024 Financial Results and Q3 2024 Sales

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Ground-Breaking Positive Clinical Results in Lung Cancer Obtained with Cellvizio 

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

Mauna Kea Technologies Announces Endorsement from The American Foregut Society for Payor Policy Coverage of Cellvizio® 

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024

Mauna Kea Technologies Announces its Sales and Achievements For the Second Quarter 2024

Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances

Mauna Kea Technologies Unveils CellTolerance, a Subsidiary Dedicated to its Unique Program for the Detection and Treatment of Food Intolerances

Mauna Kea Technologies Reports New Evidence Highly Supportive of the Use of Cellvizio for Diagnosing Pancreatic Cysts Presented at DDW 2024

Mauna Kea Technologies Reports New Evidence Highly Supportive of the Use of Cellvizio for Diagnosing Pancreatic Cysts Presented at DDW 2024

Mauna Kea Technologies announces results of its Combined General Meeting of June 6, 2024

Mauna Kea Technologies announces results of its Combined General Meeting of June 6, 2024